Understanding Drug Permeability in Pseudomonas aeruginosa

Pseudomonas aeruginosa is a Gram-negative bacterium that poses a serious threat to patients with weakened immunity, cystic fibrosis, severe burns, or those in hospitals. Its ability to resist antibiotics comes largely from its outer membrane, which blocks drug entry. This means higher doses are often needed, raising the risk of side effects. To design new treatments, researchers need drugs that not only bind strongly to bacterial targets but also cross this tough membrane. Unfortunately, there are few reliable methods to directly measure how easily drugs pass through the Pseudomonas aeruginosa cell envelope. Recent advances, such as electrophysiology-based flux studies, have started to reveal how different antibiotics particularly β-lactams move through porin channels. These studies show large differences in permeability, but the findings remain scattered. What is missing is a unified dataset that captures permeability under varied conditions. Such a resource would clarify how porin structures influence drug entry and help chemists design better compounds. This review brings together current knowledge on drug permeability in Pseudomonas aeruginosa, with a focus on electrophysiological and related methods. This review highlights the need for standardized approaches that generate consistent and comparable data. A comprehensive "permeability atlas" could guide the development of new antibiotics by fine-tuning molecular properties like size, charge, and lipophilicity, ultimately improving porin passage and restoring treatment effectiveness against this challenging pathogen.